122 related articles for article (PubMed ID: 38096154)
1. Hybrid Email and Outpatient Clinics to Optimize Maintenance Therapy in Acute Lymphoblastic Leukemia.
Mungle T; Mahadevan A; Das P; Mehta AK; Gogoi MP; Jana B; Ghara N; Ghosh D; Saha V; Krishnan S
J Pediatr Hematol Oncol; 2024 Jan; 46(1):39-45. PubMed ID: 38096154
[TBL] [Abstract][Full Text] [Related]
2. Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts?
Schmiegelow K; Nersting J; Nielsen SN; Heyman M; Wesenberg F; Kristinsson J; Vettenranta K; Schrøeder H; Weinshilboum R; Jensen KL; Grell K; Rosthoej S
Pediatr Blood Cancer; 2016 Dec; 63(12):2104-2111. PubMed ID: 27447547
[TBL] [Abstract][Full Text] [Related]
3. Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital.
Rivera GK; Pinkel D; Simone JV; Hancock ML; Crist WM
N Engl J Med; 1993 Oct; 329(18):1289-95. PubMed ID: 8413409
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of leucocyte DNA thioguanine nucleotide levels during maintenance therapy of childhood acute lymphoblastic leukemia.
Larsen RH; Hjalgrim LL; Degn M; Nersting J; Als-Nielsen B; Grell K; Schmiegelow K
Cancer Chemother Pharmacol; 2021 Jul; 88(1):53-60. PubMed ID: 33754188
[TBL] [Abstract][Full Text] [Related]
5. Maintenance chemotherapy for childhood acute lymphoblastic leukemia: should dosage be guided by white blood cell counts?
Schmiegelow K; Pulczynska MK
Am J Pediatr Hematol Oncol; 1990; 12(4):462-7. PubMed ID: 2285127
[TBL] [Abstract][Full Text] [Related]
6. Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study.
Gandemer V; Auclerc MF; Perel Y; Vannier JP; Le Gall E; Demeocq F; Schmitt C; Piguet C; Stephan JL; Lejars O; Debre M; Jonveaux P; Cayuela JM; Chevret S; Leverger G; Baruchel A;
BMC Cancer; 2009 Jan; 9():14. PubMed ID: 19144139
[TBL] [Abstract][Full Text] [Related]
7. Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia.
Schmiegelow K; Ifversen M
Pediatr Hematol Oncol; 1996; 13(5):433-41. PubMed ID: 10897815
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte-macrophage colony-stimulating factor support in therapy of high-risk acute lymphoblastic leukemia in children.
Saarinen-Pihkala UM; Lanning M; Perkkiö M; Mäkipernaa A; Salmi TT; Hovi L; Vettenranta K
Med Pediatr Oncol; 2000 May; 34(5):319-27. PubMed ID: 10797353
[TBL] [Abstract][Full Text] [Related]
9. Treatment of childhood acute lymphoblastic leukemia with delayed first intrathecal therapy and omission of prophylactic cranial irradiation: Results of the TPOG-ALL-2002 study.
Yeh TC; Liang DC; Hou JY; Jaing TH; Lin DT; Yang CP; Peng CT; Hung IJ; Lin KH; Hsiao CC; Jou ST; Chiou SS; Chen JS; Wang SC; Chang TK; Wu KH; Sheen JM; Yen HJ; Chen SH; Lu MY; Li MJ; Chang TT; Huang TH; Chang YH; Chen SH; Yang YL; Chang HH; Chen BW; Lin PC; Cheng CN; Chao YH; Yang SH; Chao YY; Liu HC
Cancer; 2018 Dec; 124(23):4538-4547. PubMed ID: 30303520
[TBL] [Abstract][Full Text] [Related]
10. Improved outcome for children with acute lymphoblastic leukemia after risk-adjusted intensive therapy: a single-institution experience.
Al-Nasser A; El-Solh H; De Vol E; El-Hassan I; Alzahrani A; Al-Sudairy R; Al-Mahr M; Al-Musa A; Al-Jefri A; Saleh M; Rifai S; Belgaumi A; Osman L; Ashraf K; Salim M; Silo A; Roberts G
Ann Saudi Med; 2008; 28(4):251-9. PubMed ID: 18596394
[TBL] [Abstract][Full Text] [Related]
11. Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia.
Nielsen SN; Grell K; Nersting J; Frandsen TL; Hjalgrim LL; Schmiegelow K
Cancer Chemother Pharmacol; 2016 Nov; 78(5):983-994. PubMed ID: 27600880
[TBL] [Abstract][Full Text] [Related]
12. A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL).
Ladas EJ; Kroll DJ; Oberlies NH; Cheng B; Ndao DH; Rheingold SR; Kelly KM
Cancer; 2010 Jan; 116(2):506-13. PubMed ID: 20014183
[TBL] [Abstract][Full Text] [Related]
13. Comparative treatment costs of risk-stratified therapy for childhood acute lymphoblastic leukemia in India.
Mungle T; Das N; Pal S; Gogoi MP; Das P; Ghara N; Ghosh D; Arora RS; Bhakta N; Saha V; Krishnan S
Cancer Med; 2023 Feb; 12(3):3499-3508. PubMed ID: 36812120
[TBL] [Abstract][Full Text] [Related]
14. Detection of anti-asparaginase antibodies during therapy with E.coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma.
Ebeid EN; Kamel MM; Ali BA
J Egypt Natl Canc Inst; 2008 Jun; 20(2):127-33. PubMed ID: 20029468
[TBL] [Abstract][Full Text] [Related]
15. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
Schmiegelow K; Bretton-Meyer U
Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
[TBL] [Abstract][Full Text] [Related]
16. Infection-related complications during treatment for childhood acute lymphoblastic leukemia.
Inaba H; Pei D; Wolf J; Howard SC; Hayden RT; Go M; Varechtchouk O; Hahn T; Buaboonnam J; Metzger ML; Rubnitz JE; Ribeiro RC; Sandlund JT; Jeha S; Cheng C; Evans WE; Relling MV; Pui CH
Ann Oncol; 2017 Feb; 28(2):386-392. PubMed ID: 28426102
[TBL] [Abstract][Full Text] [Related]
17. Granulocyte colony-stimulating factor ameliorates toxicity of intensification chemotherapy for acute lymphoblastic leukemia.
Clarke V; Dunstan FD; Webb DK
Med Pediatr Oncol; 1999 May; 32(5):331-5. PubMed ID: 10219333
[TBL] [Abstract][Full Text] [Related]
18. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia.
Schmiegelow K; Björk O; Glomstein A; Gustafsson G; Keiding N; Kristinsson J; Mäkipernaa A; Rosthøj S; Szumlanski C; Sørensen TM; Weinshilboum R
J Clin Oncol; 2003 Apr; 21(7):1332-9. PubMed ID: 12663723
[TBL] [Abstract][Full Text] [Related]
19. Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group.
Miller TP; Getz KD; Li Y; Demissei BG; Adamson PC; Alonzo TA; Burrows E; Cao L; Castellino SM; Daves MH; Fisher BT; Gerbing R; Grundmeier RW; Krause EM; Lee J; Lupo PJ; Rabin KR; Ramos M; Scheurer ME; Wilkes JJ; Winestone LE; Hawkins DS; Gramatges MM; Aplenc R
Lancet Haematol; 2022 Sep; 9(9):e678-e688. PubMed ID: 35870472
[TBL] [Abstract][Full Text] [Related]
20. Effect of NUDT15 on incidence of neutropenia in children with acute lymphoblastic leukemia.
Buaboonnam J; Sripatanatadasakul P; Treesucon A; Glomglao W; Siraprapapat P; Narkbunnam N; Vathana N; Takpradit C; Phuakpet K; Pongtanakul B; Tongsai S; Sinlapamongkolkul P; Sanpakit K
Pediatr Int; 2019 Aug; 61(8):754-758. PubMed ID: 31166660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
